Imaging of Kaposi sarcoma in a transplanted liver: A rare case report (original) (raw)
Related papers
2022
Introduction: Kaposi's Sarcoma is a multicentric malignant neoplasm characterized by the development of purple tumors, which can be seen on the skin and subcutaneous tissue and on viscera. The objective of this study was to report a case of Kaposi's Sarcoma after liver transplantation, considering the rarity of this event. Method: The research instrument used to conduct this report was the case study, with collection of information from the patient's physical record. Case report: A 28-year-old man with a history of using Tacrolimus for three years due to liver transplantation, presented abdominal pain associated with diarrhea, and was diagnosed with Kaposi's Sarcomi through histopathological examination of intestinal polyp and referred for chemotherapy treatment. Final considerations: Patients who were submitted to solid organ transplants and treated with immunodepressive medications should have any new symptoms carefully investigated to allow an early diagnosis of neoplasia.
Sarcoma de Kaposi pós-transplante hepático: relato de caso
Revista de Medicina, 2022
Introduction: Kaposi's Sarcoma is a multicentric malignant neoplasm characterized by the development of purple tumors, which can be seen on the skin and subcutaneous tissue and on viscera. The objective of this study was to report a case of Kaposi's Sarcoma after liver transplantation, considering the rarity of this event. Method: The research instrument used to conduct this report was the case study, with collection of information from the patient's physical record. Case report: A 28-year-old man with a history of using Tacrolimus for three years due to liver transplantation, presented abdominal pain associated with diarrhea, and was diagnosed with Kaposi's Sarcomi through histopathological examination of intestinal polyp and referred for chemotherapy treatment. Final considerations: Patients who were submitted to solid organ transplants and treated with immunodepressive medications should have any new symptoms carefully investigated to allow an early diagnosis of neoplasia.
Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression
Clinical transplantation, 1993
Of 1463 liver allograft recipients receiving the combination of FK506 and steroids as their primary immunosuppressive regimen, 2 patients developed Kaposi's sarcoma. Although previously described as a complication of organ transplantation, this is the first case report of Kaposi's sarcoma occurring in association with the macrolide immunosuppressive agent FK506. A discussion of the clinical presentation and course of Kaposi's sarcoma in these 2 patients, as well as a review of the past literature on Kaposi's sarcoma in organ transplant recipients, emphasizes the therapeutic difficulties encountered. Kaposi's sarcoma is also compared to lymphoproliferative disorders, another well-recognized complication of immunosuppression, highlighting the differences between these two entities.
Liver Transplantation and Surgery, 1997
Kaposi's sarcoma (KS) is a common malignancy in patients with acquired immunodeficiency syndrome (AIDS), classically appearing as red to purple plaques containing small papules and nodules. We report our experience with an adolescent orthotopic liver transplant recipient who presented with an unusual presentation of KS. The patient had a protracted multisystem illness that began with hemolytic anemia, fevers, and fatigue and progressed to pancreatitis, sinusitis, lymphadenopathy, and mouth ulcers. The diagnosis was made by a lymph node biopsy that was performed to evaluate for Epstein-Barr virus. The classical subcutaneous nodules characteristic of KS did not become evident until shortly before the patient died. We present this case to emphasize that KS in pediatric liver transplant patients can present as a multisystem disease that progresses to disseminated organ involvement before the characteristic subcutaneous manifestations are evident.
Unusual site of kaposi sarcoma after kidney transplantation
Iranian journal of kidney diseases, 2012
Kaposi sarcoma (KS) is the most common cancer after kidney transplantation in the Middle East countries. 1 The prevalence of KS in comparison with other tumors is also quite higher in Iranian recipients. 1,2 However, squamous cell carcinoma of the skin is the most common posttransplant malignancy in other reports. 1,3,4 Its incidence following kidney transplantation has steadily increased due to the long-term use of potent i m m u n o s u p p r e s s i v e d r u g s f o r p r e v e n t i o n of allograft rejection. 1,3,5 The prevalence of posttransplant KS varies in different geographic areas, most cases reported from Mediterranean descent, suggesting the importance of ethnic or environmental factors in its development. 1,3,6 Several investigators have found that the higher levels of anti-human herpesvirus-8 antibodies in the Middle East region where there is a higher prevalence of KS. 1 In the current issue of the Iranian Journal of Kidney Diseases a solitary laryngeal KS in a kidney transplant recipient is reported by Taheri and coworkers as an unusual involvement. 7 The patient who was a 40-year-old man presented with severe hoarseness after 21 months of his transplantation. It is important to note that 90% of kidney transplants with KS have skin lesions, mucosal lesions, or both. The oropharyngeal and conjunctival mucosa may be affected. Purely visceral involvement happens in 10% of recipients and their clinical manifestations are unusual. 1 Visceral disease predominantly affects the lymph nodes, gastrointestinal tract, and
Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study
Journal of the American Academy of Dermatology, 2019
Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors and/or chemotherapy. Objective: To obtain an overview of clinical strategies about the current treatment of KS. Methods: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months. Results: Ninety five percent, 28% and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. Overall, 83% of patients had response at 6 months including 40% complete responses (CR). Limitations: The retrospective design of the study. Conclusion: Currently available therapeutic options seem to be effective to control KS in a majority of patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.
Kaposi's Sarcoma after Kidney Transplantation: a 21-Years Experience
International journal of hematology-oncology and stem cell research, 2013
The long-term use of immunosuppressive agents for prevention of allograft rejection increases the risk of malignancy approximately 100 times as high as that in the general population and Kaposi's sarcoma (KS) is a relatively common malignancy after kidney transplantation. The aim of present study was to investigate the frequency of KS in patients with kidney transplantation in 20 years period. In this study Charts and pathology reports of 1487 recipients for kidney allografts treated at Imam Reza hospital between 1991 and 2012 were reviewed. The SPSS software package version 16 (SPSS Inc., Chicago, Illinois, USA) was used for the statistical analysis. There were 17 of 1487 incident cases of KS kidney transplant population at our hospital in period of study. There is no significant difference between age and gender of patients. The mean time between transplantation and non-KS malignant tumors was 34.4 ± 21.8 months (range 12-140 months), while in KS patients it was 18.7 ± 25.2 mo...